Efficacy and safety of atezolizumab as first-line therapy for metastatic non–small cell lung cancer (NSCLC) with high levels of PD-L1 expression is not known, the authors said. Treatment with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results